These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 14962585)

  • 1. Drug polymorphism and dosage form design: a practical perspective.
    Singhal D; Curatolo W
    Adv Drug Deliv Rev; 2004 Feb; 56(3):335-47. PubMed ID: 14962585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
    Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API.
    McNamara DP; Childs SL; Giordano J; Iarriccio A; Cassidy J; Shet MS; Mannion R; O'Donnell E; Park A
    Pharm Res; 2006 Aug; 23(8):1888-97. PubMed ID: 16832611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. General principles of pharmaceutical solid polymorphism: a supramolecular perspective.
    Rodríguez-Spong B; Price CP; Jayasankar A; Matzger AJ; Rodríguez-Hornedo N
    Adv Drug Deliv Rev; 2004 Feb; 56(3):241-74. PubMed ID: 14962581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase transformation considerations during process development and manufacture of solid oral dosage forms.
    Zhang GG; Law D; Schmitt EA; Qiu Y
    Adv Drug Deliv Rev; 2004 Feb; 56(3):371-90. PubMed ID: 14962587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates.
    Blagden N; de Matas M; Gavan PT; York P
    Adv Drug Deliv Rev; 2007 Jul; 59(7):617-30. PubMed ID: 17597252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Polymorph transformation of solid drugs].
    Zhang Q; Mei XF
    Yao Xue Xue Bao; 2015 May; 50(5):521-7. PubMed ID: 26234130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
    Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solution-mediated phase transformation: significance during dissolution and implications for bioavailability.
    Greco K; Bogner R
    J Pharm Sci; 2012 Sep; 101(9):2996-3018. PubMed ID: 22213419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aqueous solubility of crystalline and amorphous drugs: Challenges in measurement.
    Murdande SB; Pikal MJ; Shanker RM; Bogner RH
    Pharm Dev Technol; 2011 Jun; 16(3):187-200. PubMed ID: 20429826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.
    Morissette SL; Almarsson O; Peterson ML; Remenar JF; Read MJ; Lemmo AV; Ellis S; Cima MJ; Gardner CR
    Adv Drug Deliv Rev; 2004 Feb; 56(3):275-300. PubMed ID: 14962582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Progress in the research of amorphous pharmaceuticals].
    Ying J; Lü Y; Du GH
    Yao Xue Xue Bao; 2009 May; 44(5):443-8. PubMed ID: 19618716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-polymer solubility and miscibility: Stability consideration and practical challenges in amorphous solid dispersion development.
    Qian F; Huang J; Hussain MA
    J Pharm Sci; 2010 Jul; 99(7):2941-7. PubMed ID: 20127825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liquisolid systems and aspects influencing their research and development.
    Vraníková B; Gajdziok J
    Acta Pharm; 2013 Dec; 63(4):447-65. PubMed ID: 24451071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solid molecular dispersions of poorly water-soluble drugs in poly(2-hydroxyethyl methacrylate) hydrogels.
    Zahedi P; Lee PI
    Eur J Pharm Biopharm; 2007 Mar; 65(3):320-8. PubMed ID: 17182231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches.
    Fakes MG; Vakkalagadda BJ; Qian F; Desikan S; Gandhi RB; Lai C; Hsieh A; Franchini MK; Toale H; Brown J
    Int J Pharm; 2009 Mar; 370(1-2):167-74. PubMed ID: 19100319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk assessment and physicochemical characterization of a metastable dihydrate API phase for intravenous formulation development.
    Mortko CJ; Sheth AR; Variankaval N; Li L; Farrer BT
    J Pharm Sci; 2010 Dec; 99(12):4973-81. PubMed ID: 20821397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic in vitro and in vivo evaluation for determining the feasibility of making an amorphous solid dispersion of a B-Raf (rapidly accelerated fibrosarcoma) inhibitor.
    Cui Y; Chiang PC; Choo EF; Boggs J; Rudolph J; Grina J; Wenglowsky S; Ran Y
    Int J Pharm; 2013 Sep; 454(1):241-8. PubMed ID: 23834830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co amorphous systems: A product development perspective.
    Chavan RB; Thipparaboina R; Kumar D; Shastri NR
    Int J Pharm; 2016 Dec; 515(1-2):403-415. PubMed ID: 27771485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the glass-forming ability of active pharmaceutical ingredients for designing supersaturating dosage forms.
    Kawakami K; Usui T; Hattori M
    J Pharm Sci; 2012 Sep; 101(9):3239-48. PubMed ID: 22531946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.